
John Bell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10740857/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma. Molecular Therapy, 2008, 16, 1637-1642.	3.7	175
2	Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus. PLoS Medicine, 2007, 4, e353.	3.9	171
3	Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. Journal of Clinical Investigation, 2007, 117, 3350-3358.	3.9	165
4	Myxoma Virus Is a Novel Oncolytic Virus with Significant Antitumor Activity against Experimental Human Gliomas. Cancer Research, 2005, 65, 9982-9990.	0.4	149
5	Viruses for Tumor Therapy. Cell Host and Microbe, 2014, 15, 260-265.	5.1	131
6	Stretchable respiration sensors: Advanced designs and multifunctional platforms for wearable physiological monitoring. Biosensors and Bioelectronics, 2020, 166, 112460.	5.3	129
7	Gene–environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet, The, 2010, 375, 2143-2151.	6.3	112
8	Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin. Cancer Research, 2007, 67, 8818-8827.	0.4	97
9	Incidence of Breast Cancer and Its Subtypes in Relation to Individual and Multiple Low-Penetrance Genetic Susceptibility Loci. JAMA - Journal of the American Medical Association, 2010, 304, 426.	3.8	97
10	Myxoma Virus Virotherapy for Glioma in Immunocompetent Animal Models: Optimizing Administration Routes and Synergy with Rapamycin. Cancer Research, 2010, 70, 598-608.	0.4	90
11	Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16018.	1.8	83
12	Targeting the Apoptotic Pathway with BCL-2 Inhibitors Sensitizes Primary Chronic Lymphocytic Leukemia Cells to Vesicular Stomatitis Virus-Induced Oncolysis. Journal of Virology, 2008, 82, 8487-8499.	1.5	47
13	Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro-Oncology, 2013, 15, 904-920.	0.6	44
14	Oncolysis of Prostate Cancers Induced by Vesicular Stomatitis Virus in PTEN Knockout Mice. Cancer Research, 2010, 70, 1367-1376.	0.4	40
15	VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia. Molecular Therapy, 2010, 18, 2094-2103.	3.7	34
16	Bax-dependent mitochondrial membrane permeabilization enhances IRF3-mediated innate immune response during VSV infection. Virology, 2007, 365, 20-33.	1.1	31
17	Vesicular Stomatitis Virus Oncolysis of T Lymphocytes Requires Cell Cycle Entry and Translation Initiation. Journal of Virology, 2008, 82, 5735-5749.	1.5	29
18	Doubleâ€deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Molecular Oncology, 2013, 7, 944-954.	2.1	26

John Bell

#	Article	IF	CITATIONS
19	Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis. International Journal of Cancer, 2014, 134, 717-730.	2.3	16
20	Redefining disease. Clinical Medicine, 2010, 10, 584-594.	0.8	13
21	The concept of light-harvesting, self-powered mechanical sensors using a monolithic structure. Nano Energy, 2022, 96, 107030.	8.2	10
22	Combining Oncolytic Viruses with Cancer Immunotherapy. , 2011, , 339-355.		0